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Radiotherapy for local recurrences of endometrial cancer
after surgery and vaginal brachytherapy
Grzegorz Panek, Jan Zieliƒski, Gra˝yna Kamiƒska, Ryszard Krynicki
A i m. The aim of the study was to evaluate the effectiveness of radiotherapy for local recurrences of endometrial cancer after
primary surgery and vaginal brachytherapy.
M a t e r i a l  a n d m e t h o d s.  Forty one patients with histopathologically proven local recurrences of endometrial cancer
were treated in years 1990-1998. The treatment of recurrences consisted of external beam irradiation of the pelvis (mean do-
se 46 Gy) plus intracavitary brachytherapy LDR/MDR with dose of 40-45 Gy at 0.5 cm below the surface of the mucosa. Fol-
low-up ranged from 6 to 60 months (median 19 months). Survival curve was calculated with Kaplan-Meier method. The log-
-rank test was used to evaluate the influence of the following prognostic factors on the survival: time from the completion of
primary treatment to the diagnosis of recurrence, and localisation of the relapsing tumor.
Re s u l t s.  The probability of survival of 3 and 5 years was 0.33 and 0.21. Both analysed prognostic factors – time to the dia-
gnosis and localisation of the recurrence had a satisfically significant influence on survival. The risk of death from the dise-
ase was significantly higher with extravaginal spread of the tumor and with the time gap of less than 1 year after completion
of primary treatment. (Relative risk 1.40 and 1.44, 95% C.I.)
C o n c l u s i o n.  The results of treatment, confirmed a very serious prognosis in this particular group of patients, with the use
of presently available methods of treatment. Better methods of identification of prognostic factors which might be predictive
of developing a recurrence are reguired. Better methods of early detection of relapses and more effective treatment may con-
tribute to the better survival of these high risk patients.
Wyniki napromieniania nawrotów miejscowych raka b∏ony Êluzowej macicy
po pierwotnym leczeniu operacyjnym i dopochwowej brachyterapii
C e l  p r a c y.  Celem pracy by∏a ocena wyników radioterapii nawrotów miejscowych raka b∏ony Êluzowej macicy po pierwot-
nym leczeniu operacyjnym i brachyterapii dopochwowej.
M a t e r i a ∏  i m e t o d y.  Przedmiotem analizy by∏o 41 chorych z nawrotem miejscowym raka b∏ony Êluzowej macicy, któ-
ry rozpoznano i leczono w Klinice Nowotworów Narzàdów P∏ciowych Kobiecych Centrum Onkologii w Warszawie w la-
tach 1990-1998. W leczeniu nawrotów stosowano teleradioterapi´ na obszar miednicy ma∏ej w Êredniej dawce 46 Gy, w cz´-
Êci przypadków brachyterapi´ dopochwowà w dawce 40-45 Gy na g∏´bokoÊci 5 mm od powierzchni Êciany pochwy. Okres
obserwacji po zakoƒczeniu leczenia nawrotów wynosi∏ od 6 do 60 miesi´cy (mediana 19 miesi´cy). Metodà Kaplana-Me-
iera wyznaczono krzywà prze˝ycia analizowanej grupy chorych. Pos∏ugujàc si´ testem log-rank oceniono wp∏yw wybranych
czynników prognostycznych na prze˝ycia: czas wystàpienia nawrotu od zakoƒczenia leczenia pierwotnego oraz lokalizacja
nawrotu.
W y n i k i.  Obliczone metodà Kaplana-Meiera prawdopodobieƒstwo 3 letniego prze˝ycia wynosi∏o 0,33, a 5 letniego 0,21.
W analizie wp∏ywu czynników prognostycznych na prze˝ycia, zarówno lokalizacja nawrotu, jak i czas od zakoƒczenia leczenia
pierwotnego, by∏y znamienne statystyczne. Ryzyko zgonu by∏o znamiennie wy˝sze u chorych z spoza pochwowym szerzeniem si´
nowotworu oraz przy czasie wystàpienia nawrotu krótszym ni˝ jeden rok (wspó∏czynnik ryzyka wynosi∏ odpowiednio 1,40
i 1,44, 95% (przedzia∏ ufnoÊci).
W n i o s k i.  Wyniki analizy obserwacji 41 kobiet z nawrotem miejscowym raka b∏ony Êluzowej macicy potwierdzi∏y powa˝-
ne rokowanie w tej grupie chorych. Wskazuje to na pilnà potrzeb´ identyfikacji istotnych czynników prognostycznych, wp∏ywa-
jàcych na wybór leczenia uzupe∏niajàcego po pierwotnym leczeniu operacyjnym, co pozwoli∏oby zmniejszyç cz´stoÊç wyst´po-
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Carcinoma of endometrium is the second most common
malignancy of the female genital tract in Poland [1]. A ste-
ady increase of incidence over the last decades is similar
to the trend observed in other developed countries. In
majority of cases it is diagnosed in clinical stage I -FIGO
[2], when radical surgery and vaginal brachytherapy re-
sults in 90% 5-year survival [3]. However, in some cases
recurrences occur. They are usually localised in the vagi-
na or pelvis. The incidence of recurrences depends on
clinical stage of the disease and the method of primary
treatment. About 10-15% cases treated with surgery alo-
ne have central recurrence confined to the vagina [4].
The reccurence rate may be lowered to 4-5% with the
implementation of postoperative vaginal brachytherapy
[4]. Radiotherapy plays a major role in the treatment of
relapsing endometrial cancer after surgery. About 25-30
% of women can be cured by this modality [5-7]. The au-
thors present their results of radiotherapy for local re-
currences of stage I endometrial cancer after primary
surgery and adjuvant vaginal brachytherapy.
Material and methods
From January 1990 to December 1998, 41 women were tre-
ated with radiotherapy for local recurrences of endometrial
carcinoma.
The primary treatment consisted of total abdominal hy-
sterectomy and bilateral salpingooophorectomy in 29 patients,
and hysterectomy plus pelvic lymphadenectomy in 12 patients.
The microscopic examination confirmed the diagnosis of well
and moderately differenciated adenocarcinoma of endome-
tium with superficial myometrial invasion. All patients were
treated postoperatively with vaginal brachytherapy. The tre-
atment was conducted with afterloading LDR and HDR tech-
nique. The dose of 45 Gy for LDR and 21 Gy for HDR was gi-
ven at 5 mm below the surface of the vaginal mucosa. After the
completion of treatment all patients were followed up every 3-
-4 months for the first two years. A recurrence was diagnosed
2-30 months after initial treatment and confirmed microscopi-
cally in all analysed patients. A specimen for microscopic exa-
mination was obtained with punch biopsy, fine needle aspira-
tion or explorative laparotomy. Modern image techniques like
CT, NMR were used to exclude the existence of distant meta-
stases.
External beam irradiation was the principal form of treat-
ment for local relapses. A two parallel opposed or four – field
box technique was employed for pelvic irradiation. The total
dose delivered to the pelvis was 46-50 Gy, with fractions of 1.8
Gy. Patients with the tumour localised in the distal part of the va-
gina received additional intracavitary irradiation with the dose of
45 Gy at 5mm – Cs137 LDR. Median follow-up was 19 months
(range 4-60 months). Survival analysis using Kaplan-Meier me-
thod was used to calculate survival curve [8].
The influence of the following prognostic factors on su-
rvival was evaluated with the Cox model of proportional ha-
zards: localisation of the recurrence and time gap from primary
treatment to the diagnosis of it. Backword method was used to
select the variables statistically significant at p = 0.05.
Results
The clinical data on 41 patients with locally recurrent en-
dometrial cancer is presented in Table I.




median (25%,75%) 68.0 64.7
I A 3 (7.3%)
Clinical stage I B 26 (63.4%)
I C 12 (29.3%)
G-1 16 (39.0%)
Histopathological grading G-2 22 (53.7%)
G-3 3 (7.3%)
Time (months) to the to 12 months 16 (39.0%)
diagnosis of recurrence 13-24 17 (41.5%)
25-36 8 (19.5%
Median age at the time of relapse was 64 years (ran-
ge 44-81), 75% of women were younger than 70 years.
In 39% of patients, a recurrence was diagnosed within
the first, and in 80% – within two years after primary tre-
atment.
In none of 41 women a recurrence was diagnosed
later than 36 months after initial surgery. Sites of recur-
rences are presented in Table II.
Tab. II. Site of recurrences
Site No. of patients (%)
vaginal apex 9 (22.0)
distal vagina 12 (29.0)
suburethral region 6 (14.7)
vagina + parametria 10 (24.5)
inguinal nodes 2 (4.9)
pelvic nodes 2 (4.9)
Total 41 (100)
Vagina was the most frequent site of tumour a – 21
patients (51%). Vaginal recurrence with parametrial
extension was diagnosed in 10 patients (24.5%). Subure-
wania nawrotów. Nadal istnieje koniecznoÊç poszukiwania skuteczniejszych metod diagnostyki i terapii wznów raka b∏ony Êlu-
zowej macicy.
Key words: endometrial cancer, local recurrence, radiotherapy
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thral region was the site of recurrence in 6 cases (14.7%).
The probability of surviving 3 and 5 years (calculated
with Kaplan-Meier method) was 0.33 and 0.21, respecti-
vely. Overall survival curve is presented on Figure 1.
Both prognostic factors analysed: site of the recur-
rence and time to the diagnosis had a statistically signifi-
cant influence on survival (p≤0.05).
Women with a parametrial spread of the disease,
and in whom a recurrence was diagnosed within a year
after primary therapy, had a significantly higher risk of de-
ath (risk factor of 1.40 and 1.44 respectively, 95% C.I. =
0.99 and 1.97).
Discussion
Local recurrences are the major causes of treatment fa-
ilure in endometrial cancer. About 10-15% of women
recur even in early clinical stages and with good progno-
stic factors [6, 9-11]. The vagina is the principal site of re-
currence, however parametria and pelvic nodes are also
frequently involved. A mechanism of recurrence forma-
tion is not entirely clear. A subclinical extrauterine spre-
ad of the disease might be responsible for their deve-
lopment [12]. Observation of clinical relapses diagnosed
shortly after radical surgery support this hypothesis. A ro-
utine implementation of surgical – pathological staging
for a precise recognition of all important prognostic fac-
tors seems to be a reasonable approach to find the opti-
mal adjuvant treatment and limit the risk of treatment fa-
ilure.
Both surgery and radiotherapy play a major role in
the treatment of local recurrences of endometrial can-
cer [6]. The final selection of treatment method depends
on the site of the tumour (technical feasibility of radical
surgical excision) or a history of previous irradiation. No-
ne of the treatment methods presently available give a sa-
tisfactory results.
In a majority of reports only 20-30% of women tre-
ated for recurrence survive a 5-year period [5, 6]. Our
study shows a 3-year and 5-year survival of 33% and 21%,
respectively, and supports the thesis of poor prognosis
in those patients. Only a few reports demonstrate the da-
ta indicating a better prognosis in patients with tumours li-
mited to the distal part of the vagina, suitable for radical
surgery [6,13]. In this selected group of patients, a 5-year
survival of about 40% can be achieved [6]. Several au-
thors suggest, that the site of the recurrence is one of the
most important prognostic factors [5, 6, 14]. In our study,
the site of the tumour had a significat influence on the su-
rvival. Patients with parametrial spread of the disease or
positive pelvic nodes had significantly higher risk of death
than those with the tumour limited to the vaginal wall.
None of the patients in the high risk group survived a pe-
riod of more than 30 months. Other authors suggest, that
the localisation of the recurrence in the distal part of the
vagina offers a better chances for radical surgical exci-
sion or successful interstitial or intracavitary brachythera-
py [6,12].
Many authors investigated the influence of histo-
logical grade on the survival. Hart et al. indicated a si-
gnificantly worse prognosis in patients with Grade 3 tu-
mours than with Grade 1 and 2. Grading has not been
included in this analysis because majority of patients
had Grade 1 and 2 tumours. It is worth stressing that no-
ne of women with Grade 3 lesion survived a period of 30
months.
Time relapsing from the end of primary treatment to
the diagnosis of recurrence is not only an important pro-
gnostic factor but also plays a considerable role in the
selection of secondary treatment [3]. Most authors de-
monstrated a survival advantage if the time gap to the
diagnosis exceeded two years [5, 6]. In the current re-
port, a statistically significant survival advantage has been
noted when the time gap was longer than one year. Sears
et al. also found a significant survival benefit (70 vs. 40%
alive at 5 years) if the relapse-free survival was longer
than one year.
Clinical experience with the currently available me-
thods of treatment of recurrent endometrial cancer (sur-
gery, irradiation, chemo- and hormonotherapy) show a li-
mited effectiveness in curing the disease. Every effort
should be made to recognise subclinical extrauterine spre-
ad of cancer to lower the risk of failure of primary treat-
ment. This goal might be accomplished with wider ap-
plication of surgical-pathological staging [12]. An impor-
tant clinical information obtained from a precise staging
procedure may indicate the need for adjuvant treatment.
Postoperative radiotherapy – both external beam irradia-
tion to the pelvis and intracavitary irradiation is routine-
ly used in high risk patients. Its effectiveness is demonstra-
ted by a higher rate of local control and longer disease-
-free survival [15]. However some controversies about
the role of postoperative pelvic irradiation still exist be-
cause of the lack of clinical data based on prospective
randomised studies. Therefore some advocate the use of
postoperative radiotherapy at the time of recurrence [15].
In the recent study by Jereczek-Fossa, the results of radio-
therapy in 73 patients with locally relapsing endometrial
cancer confirmed a very disappointing results of treat-
ment initiated at the time of relapse[7]. A 3-year and 5-
-year survival was 33% and 25%, respectively, leading
the authors to the conclusion that pelvic irradiation given
Fig. 1. Overall survival
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postoperatively could have prevented developing of at
least some recurrences. Ackerman et al. in a retrospecti-
ve study assessed the results of adjuvant pelvic radiothe-
rapy vs. salvage irradiation at the time of recurrence. The
authors concluded, that in low risk patients (Grade 1 and
2 tumour with myometrial invasion of less than 50%)
there is a marginal survival benefit in favour of irradiated
group – 93% vs. 97%. In the high risk group (Grade 3 or
any Grade with deep myometrial invasion) the survival
advantage for pelvic adjuvant irradiation is more promi-
nent – 90% vs. 80%, respectively, confirming the value of
adjuvant treatment.
Local recurrences of endometrial cancer after prima-
ry surgery and adjuvant brachytherapy form a rare but
very serious clinical problem. Radiotherapy seems to be
the most effective method of treatment. About 30% of
patients can be cured. This results are far from satisfacto-
ry and indicate the need for an intensive search for new
methods of treatment.
Grzegorz Panek M.D. Ph.D
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